Oct. 14, 2013
(NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold its 2013 Annual Meeting of Stockholders on
Thursday, December 12, 2013
8:00 a.m. Central time
at the Marriott Hotel located at 300 East Fourth Street in
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.
The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit
Investor Relations Contact:
Liolios Group, Inc.
SOURCE Vermillion, Inc.